ReviewArchives of pharmacal research2022

Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.

Faraat Ali et al.PubMed ↗Publisher ↗

No numbers read from the abstract.